A comprehensive study of the spatiotemporal pattern of β-amyloid precursor protein mRNA and protein in the rat brain: Lack of modulation by exogenously applied nerve growth factor

Rachael L. Neve, Janice S. Valletta, Yiwen Li, Montserrat Ventosa-Michelman, David M. Holtzman, William C. Mobley

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Nerve growth factor (NGF) is a neurotrophic factor for basal forebrain cholinergic neurons, a population that degenerates and dies in Alzheimer's disease (AD). It has been suggested that NGF be used to treat AD patients. However, in vivo administration of NGF to the developing hamster brain was shown to induce the expression of the β-amyloid precursor protein (βAPP) gene. The association of alterations in βAPP gene expression with AD-like neuropathological changes and cognitive impairment in animals, and with AD-like neurodegeneration in Down syndrome patients suggests that NGF-mediated increases in βAPP expression could negate or attenuate NGF's neurotrophic activity in AD treatment trials. The present study was undertaken to explore further the influence of NGF on βAPP expression, and to determine which, if any, of the βAPP mRNAs is altered in response to NGF treatment. We first examined the spatiotemporal pattern of βAPP-695 and Kunitz protease inhibitor (KPI)-containing βAPP mRNA expression in the rat brain. Specific oligonucleotide probes were used to show that these mRNAs are present during embryonic development. In addition, we evaluated postnatal expression in nine brain regions and showed that βAPP mRNAs were readily detected in all regions at postnatal day 2. In human brain, the relative levels of βAPP-695 and βAPP-KPI mRNA and their protein are discordant, in that the level of βAPP-695 mRNA is slightly higher than that of βAPP-KPI, but βAPP-KPI protein predominates. In contrast, the several-fold excess of βAPP-695 mRNA relative to βAPP-KPI mRNA in the rat brain was also reflected at the protein level. Surprisingly, administration of exogenous NGF failed to affect rat βAPP mRNA levels either in vitro or during postnatal development in vivo.

Original languageEnglish
Pages (from-to)185-197
Number of pages13
JournalMolecular Brain Research
Volume39
Issue number1-2
DOIs
StatePublished - Jul 1 1996
Externally publishedYes

Fingerprint

Amyloid beta-Protein Precursor
Nerve Growth Factor
Messenger RNA
Brain
Proteins
Protease Inhibitors
Alzheimer Disease
Cholinergic Neurons
Oligonucleotide Probes
Nerve Growth Factors
Down Syndrome
Cricetinae

Keywords

  • Alzheimer's disease
  • Gene expression
  • Nerve growth factor

ASJC Scopus subject areas

  • Molecular Biology
  • Cellular and Molecular Neuroscience

Cite this

A comprehensive study of the spatiotemporal pattern of β-amyloid precursor protein mRNA and protein in the rat brain : Lack of modulation by exogenously applied nerve growth factor. / Neve, Rachael L.; Valletta, Janice S.; Li, Yiwen; Ventosa-Michelman, Montserrat; Holtzman, David M.; Mobley, William C.

In: Molecular Brain Research, Vol. 39, No. 1-2, 01.07.1996, p. 185-197.

Research output: Contribution to journalArticle

Neve, Rachael L. ; Valletta, Janice S. ; Li, Yiwen ; Ventosa-Michelman, Montserrat ; Holtzman, David M. ; Mobley, William C. / A comprehensive study of the spatiotemporal pattern of β-amyloid precursor protein mRNA and protein in the rat brain : Lack of modulation by exogenously applied nerve growth factor. In: Molecular Brain Research. 1996 ; Vol. 39, No. 1-2. pp. 185-197.
@article{aeb5981144bd4b6d878dd257341cb710,
title = "A comprehensive study of the spatiotemporal pattern of β-amyloid precursor protein mRNA and protein in the rat brain: Lack of modulation by exogenously applied nerve growth factor",
abstract = "Nerve growth factor (NGF) is a neurotrophic factor for basal forebrain cholinergic neurons, a population that degenerates and dies in Alzheimer's disease (AD). It has been suggested that NGF be used to treat AD patients. However, in vivo administration of NGF to the developing hamster brain was shown to induce the expression of the β-amyloid precursor protein (βAPP) gene. The association of alterations in βAPP gene expression with AD-like neuropathological changes and cognitive impairment in animals, and with AD-like neurodegeneration in Down syndrome patients suggests that NGF-mediated increases in βAPP expression could negate or attenuate NGF's neurotrophic activity in AD treatment trials. The present study was undertaken to explore further the influence of NGF on βAPP expression, and to determine which, if any, of the βAPP mRNAs is altered in response to NGF treatment. We first examined the spatiotemporal pattern of βAPP-695 and Kunitz protease inhibitor (KPI)-containing βAPP mRNA expression in the rat brain. Specific oligonucleotide probes were used to show that these mRNAs are present during embryonic development. In addition, we evaluated postnatal expression in nine brain regions and showed that βAPP mRNAs were readily detected in all regions at postnatal day 2. In human brain, the relative levels of βAPP-695 and βAPP-KPI mRNA and their protein are discordant, in that the level of βAPP-695 mRNA is slightly higher than that of βAPP-KPI, but βAPP-KPI protein predominates. In contrast, the several-fold excess of βAPP-695 mRNA relative to βAPP-KPI mRNA in the rat brain was also reflected at the protein level. Surprisingly, administration of exogenous NGF failed to affect rat βAPP mRNA levels either in vitro or during postnatal development in vivo.",
keywords = "Alzheimer's disease, Gene expression, Nerve growth factor",
author = "Neve, {Rachael L.} and Valletta, {Janice S.} and Yiwen Li and Montserrat Ventosa-Michelman and Holtzman, {David M.} and Mobley, {William C.}",
year = "1996",
month = "7",
day = "1",
doi = "10.1016/0169-328X(96)00007-1",
language = "English",
volume = "39",
pages = "185--197",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",
number = "1-2",

}

TY - JOUR

T1 - A comprehensive study of the spatiotemporal pattern of β-amyloid precursor protein mRNA and protein in the rat brain

T2 - Lack of modulation by exogenously applied nerve growth factor

AU - Neve, Rachael L.

AU - Valletta, Janice S.

AU - Li, Yiwen

AU - Ventosa-Michelman, Montserrat

AU - Holtzman, David M.

AU - Mobley, William C.

PY - 1996/7/1

Y1 - 1996/7/1

N2 - Nerve growth factor (NGF) is a neurotrophic factor for basal forebrain cholinergic neurons, a population that degenerates and dies in Alzheimer's disease (AD). It has been suggested that NGF be used to treat AD patients. However, in vivo administration of NGF to the developing hamster brain was shown to induce the expression of the β-amyloid precursor protein (βAPP) gene. The association of alterations in βAPP gene expression with AD-like neuropathological changes and cognitive impairment in animals, and with AD-like neurodegeneration in Down syndrome patients suggests that NGF-mediated increases in βAPP expression could negate or attenuate NGF's neurotrophic activity in AD treatment trials. The present study was undertaken to explore further the influence of NGF on βAPP expression, and to determine which, if any, of the βAPP mRNAs is altered in response to NGF treatment. We first examined the spatiotemporal pattern of βAPP-695 and Kunitz protease inhibitor (KPI)-containing βAPP mRNA expression in the rat brain. Specific oligonucleotide probes were used to show that these mRNAs are present during embryonic development. In addition, we evaluated postnatal expression in nine brain regions and showed that βAPP mRNAs were readily detected in all regions at postnatal day 2. In human brain, the relative levels of βAPP-695 and βAPP-KPI mRNA and their protein are discordant, in that the level of βAPP-695 mRNA is slightly higher than that of βAPP-KPI, but βAPP-KPI protein predominates. In contrast, the several-fold excess of βAPP-695 mRNA relative to βAPP-KPI mRNA in the rat brain was also reflected at the protein level. Surprisingly, administration of exogenous NGF failed to affect rat βAPP mRNA levels either in vitro or during postnatal development in vivo.

AB - Nerve growth factor (NGF) is a neurotrophic factor for basal forebrain cholinergic neurons, a population that degenerates and dies in Alzheimer's disease (AD). It has been suggested that NGF be used to treat AD patients. However, in vivo administration of NGF to the developing hamster brain was shown to induce the expression of the β-amyloid precursor protein (βAPP) gene. The association of alterations in βAPP gene expression with AD-like neuropathological changes and cognitive impairment in animals, and with AD-like neurodegeneration in Down syndrome patients suggests that NGF-mediated increases in βAPP expression could negate or attenuate NGF's neurotrophic activity in AD treatment trials. The present study was undertaken to explore further the influence of NGF on βAPP expression, and to determine which, if any, of the βAPP mRNAs is altered in response to NGF treatment. We first examined the spatiotemporal pattern of βAPP-695 and Kunitz protease inhibitor (KPI)-containing βAPP mRNA expression in the rat brain. Specific oligonucleotide probes were used to show that these mRNAs are present during embryonic development. In addition, we evaluated postnatal expression in nine brain regions and showed that βAPP mRNAs were readily detected in all regions at postnatal day 2. In human brain, the relative levels of βAPP-695 and βAPP-KPI mRNA and their protein are discordant, in that the level of βAPP-695 mRNA is slightly higher than that of βAPP-KPI, but βAPP-KPI protein predominates. In contrast, the several-fold excess of βAPP-695 mRNA relative to βAPP-KPI mRNA in the rat brain was also reflected at the protein level. Surprisingly, administration of exogenous NGF failed to affect rat βAPP mRNA levels either in vitro or during postnatal development in vivo.

KW - Alzheimer's disease

KW - Gene expression

KW - Nerve growth factor

UR - http://www.scopus.com/inward/record.url?scp=0029892692&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029892692&partnerID=8YFLogxK

U2 - 10.1016/0169-328X(96)00007-1

DO - 10.1016/0169-328X(96)00007-1

M3 - Article

C2 - 8804727

AN - SCOPUS:0029892692

VL - 39

SP - 185

EP - 197

JO - Brain Research

JF - Brain Research

SN - 0006-8993

IS - 1-2

ER -